GLP-1 weight loss shots: separating facts from TikTok hype

What did @younannowzaradan2 actually say?

The creator, who presents as Dr. Younan Nowzaradan's son based on the account name, told 1.4 million viewers that GLP-1 weight loss injections "not only make you lose fat, they also make you lose muscle mass." The fix, according to him: "daily exercise" to prevent that muscle loss. He also flagged that there are "unknown side effects" still being studied.

The core claim is simple enough to fact-check. GLP-1 drugs cause weight loss, some of that weight loss comes from lean mass, and exercise may help preserve muscle. But the way he framed it, and the word "daily," deserve a closer look before you take this as clinical guidance.

Does the science back this up?

Mostly, yes. The muscle loss concern is real and documented, though the framing of "daily exercise" as the solution is more hopeful than precise.

Research published by Wilding et al. (2021, NEJM) on semaglutide showed participants lost roughly 15% of body weight, but a meaningful portion of that was lean mass, not just fat. A 2023 analysis by Garvey et al. in Nature Medicine found that on tirzepatide, lean mass loss accounted for approximately 25-39% of total weight lost, depending on dose. That is consistent with what happens in most caloric-deficit weight loss scenarios, GLP-1 or otherwise. These drugs do not specifically target fat while ignoring muscle. Rapid weight loss through any mechanism tends to take some muscle with it.

On exercise: resistance training has solid evidence for preserving lean mass during weight loss. A 2024 trial by Ard et al. (Obesity) specifically tested semaglutide plus resistance training versus semaglutide alone and found the exercise group preserved significantly more lean mass. So the recommendation is grounded in real data, not wishful thinking.

What did they get wrong (or right)?

He got the core biology right. Muscle loss during GLP-1 therapy is a legitimate clinical concern, not a fringe talking point, and the mainstream medical community has been increasingly vocal about it. Credit where it is due.

What he got imprecise: the word "daily" is not what the evidence actually recommends. Resistance training guidelines for muscle preservation during weight loss typically suggest two to three sessions per week, not daily. Daily resistance training without adequate recovery can actually impair muscle protein synthesis. He likely meant "regular" exercise, but precision matters when 1.4 million people are listening.

He also said there are side effects "we still don't know about," which is technically true of any relatively new drug class, but framing it vaguely without context adds anxiety without information. The known side effect profile of semaglutide and tirzepatide, nausea, gastrointestinal issues, rare pancreatitis risk, is reasonably well-characterized at this point from large-scale trials. Saying "unknown unknowns" without grounding it is not especially useful to patients.

He did not recommend doses, compare compounded versions to brand-name drugs, or make any disease-cure claims. That is worth noting. The video is imperfect, but it is not dangerous.

What should you actually know?

If you are on a GLP-1 medication, the muscle loss concern is worth taking seriously, but not panicking over. Here is what the evidence actually supports.

• Lean mass loss during GLP-1 therapy is real, but it is not unique to these drugs. Any significant caloric deficit produces some muscle loss. The proportion tends to be higher with faster weight loss.
• Resistance training, specifically lifting weights or using resistance bands, is the most evidence-backed intervention for preserving lean mass. Two to three sessions per week is the standard recommendation from sports medicine and obesity medicine guidelines.
• Adequate protein intake matters just as much, if not more. Research by Paddon-Jones et al. (2008, American Journal of Clinical Nutrition) established that higher protein diets help protect lean mass during caloric restriction. Most obesity medicine clinicians recommend 1.2 to 1.6 grams of protein per kilogram of body weight during active weight loss phases.
• The long-term cardiovascular and metabolic benefits of GLP-1 drugs are substantial and documented. The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major cardiovascular events with semaglutide in high-risk patients. The muscle loss concern does not negate those benefits. It means you should pair these medications with a real exercise plan.
• If you are concerned about your muscle mass specifically, ask your provider about DEXA scans or other body composition tracking. Scale weight alone does not tell you what you are losing.